BuChE-K and APOE ε4 Allele Frequencies in Lewy Body Dementias, and Influence of Genotype and Hyperhomocysteinemia on Cognitive Decline
Identifieur interne : 000F59 ( PascalFrancis/Checkpoint ); précédent : 000F58; suivant : 000F60BuChE-K and APOE ε4 Allele Frequencies in Lewy Body Dementias, and Influence of Genotype and Hyperhomocysteinemia on Cognitive Decline
Auteurs : Roger Lane [États-Unis] ; YUNSHENG HE [États-Unis] ; Christopher Morris [Royaume-Uni] ; James B. Leverenz [États-Unis] ; Murat Emre [Turquie] ; Clive Ballard [Royaume-Uni]Source :
- Movement disorders [ 0885-3185 ] ; 2009.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Apolipoprotein E (APOE) e4 and butyrylcholinesterase-K (BuChE-K) are associated with an increased risk for Alzheimer's disease. The primary objective was to evaluate frequencies of these alleles in dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD). A secondary objective was to evaluate influences on rate of cognitive decline. This analysis used data from participants consenting to pharmacogenetic testing in placebo-controlled rivastigmine studies. Allele frequencies in DLB and PDD were compared using logistic regression. Within the PDD placebo sample, associations with cognitive decline were evaluated (the DLB sample was too small for these evaluations). Fifty-seven DLB and 323 PDD subjects provided APOE and BuChE data. Allelic frequencies were higher in DLB, relative to PDD subjects, for BuChE-K (P = 0.06), APOE e4 (P < 0.001), or both alleles together (P < 0.001). More rapid cognitive decline was seen in PDD patients carrying both alleles, compared with other genotypes. Subjects with hyperhomocysteinemia were associated with more rapid decline in the presence of BuChE-K, with or without APOE ε4. These results suggest that genetic and biochemical risk factors for AD and PDD pathology may be important in dementia onset and progression in these Lewy body disorders.
Affiliations:
- Royaume-Uni, Turquie, États-Unis
- Angleterre, Grand Londres, Massachusetts, New Jersey, Washington (État)
- Londres, Seattle
- Université de Washington
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:09-0136787Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">BuChE-K and APOE ε4 Allele Frequencies in Lewy Body Dementias, and Influence of Genotype and Hyperhomocysteinemia on Cognitive Decline</title><author><name sortKey="Lane, Roger" sort="Lane, Roger" uniqKey="Lane R" first="Roger" last="Lane">Roger Lane</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Novartis Pharmaceuticals Corporation</s1><s2>East Hanover, New Jersey</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Yunsheng He" sort="Yunsheng He" uniqKey="Yunsheng He" last="Yunsheng He">YUNSHENG HE</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Clinical Pharmacogenetics, Novartis Pharmaceuticals Corporation</s1><s2>Cambridge, Massachusetts</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Morris, Christopher" sort="Morris, Christopher" uniqKey="Morris C" first="Christopher" last="Morris">Christopher Morris</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Newcastle General Hospital</s1><s2>Newcastle upon Tyne</s2><s3>GBR</s3><sZ>3 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>Newcastle General Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Leverenz, James B" sort="Leverenz, James B" uniqKey="Leverenz J" first="James B." last="Leverenz">James B. Leverenz</name><affiliation wicri:level="4"><inist:fA14 i1="04"><s1>VA-Puget Sound Health Care System (MIRECC, PADRECC) and University of Washington</s1><s2>Seattle, Washington</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Istanbul Faculty of Medicine, Istanbul University</s1><s2>Istanbul</s2><s3>TUR</s3><sZ>5 aut.</sZ></inist:fA14><country>Turquie</country><wicri:noRegion>Istanbul</wicri:noRegion></affiliation></author><author><name sortKey="Ballard, Clive" sort="Ballard, Clive" uniqKey="Ballard C" first="Clive" last="Ballard">Clive Ballard</name><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Wolfson Centre for Age Related Diseases, King's College</s1><s2>London</s2><s3>GBR</s3><sZ>6 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">09-0136787</idno><date when="2009">2009</date><idno type="stanalyst">PASCAL 09-0136787 INIST</idno><idno type="RBID">Pascal:09-0136787</idno><idno type="wicri:Area/PascalFrancis/Corpus">000F69</idno><idno type="wicri:Area/PascalFrancis/Curation">001D50</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000F59</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">BuChE-K and APOE ε4 Allele Frequencies in Lewy Body Dementias, and Influence of Genotype and Hyperhomocysteinemia on Cognitive Decline</title><author><name sortKey="Lane, Roger" sort="Lane, Roger" uniqKey="Lane R" first="Roger" last="Lane">Roger Lane</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Novartis Pharmaceuticals Corporation</s1><s2>East Hanover, New Jersey</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Yunsheng He" sort="Yunsheng He" uniqKey="Yunsheng He" last="Yunsheng He">YUNSHENG HE</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Clinical Pharmacogenetics, Novartis Pharmaceuticals Corporation</s1><s2>Cambridge, Massachusetts</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Morris, Christopher" sort="Morris, Christopher" uniqKey="Morris C" first="Christopher" last="Morris">Christopher Morris</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Newcastle General Hospital</s1><s2>Newcastle upon Tyne</s2><s3>GBR</s3><sZ>3 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>Newcastle General Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Leverenz, James B" sort="Leverenz, James B" uniqKey="Leverenz J" first="James B." last="Leverenz">James B. Leverenz</name><affiliation wicri:level="4"><inist:fA14 i1="04"><s1>VA-Puget Sound Health Care System (MIRECC, PADRECC) and University of Washington</s1><s2>Seattle, Washington</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Istanbul Faculty of Medicine, Istanbul University</s1><s2>Istanbul</s2><s3>TUR</s3><sZ>5 aut.</sZ></inist:fA14><country>Turquie</country><wicri:noRegion>Istanbul</wicri:noRegion></affiliation></author><author><name sortKey="Ballard, Clive" sort="Ballard, Clive" uniqKey="Ballard C" first="Clive" last="Ballard">Clive Ballard</name><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Wolfson Centre for Age Related Diseases, King's College</s1><s2>London</s2><s3>GBR</s3><sZ>6 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2009">2009</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Apolipoprotein E</term><term>Cognitive disorder</term><term>Genotype</term><term>Hyperhomocysteinemia</term><term>Lewy body dementia</term><term>Nervous system diseases</term><term>Parkinson disease</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Démence à corps de Lewy</term><term>Hyperhomocystéinémie</term><term>Trouble cognitif</term><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term><term>Génotype</term><term>Apolipoprotéine E</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Apolipoprotein E (APOE) e4 and butyrylcholinesterase-K (BuChE-K) are associated with an increased risk for Alzheimer's disease. The primary objective was to evaluate frequencies of these alleles in dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD). A secondary objective was to evaluate influences on rate of cognitive decline. This analysis used data from participants consenting to pharmacogenetic testing in placebo-controlled rivastigmine studies. Allele frequencies in DLB and PDD were compared using logistic regression. Within the PDD placebo sample, associations with cognitive decline were evaluated (the DLB sample was too small for these evaluations). Fifty-seven DLB and 323 PDD subjects provided APOE and BuChE data. Allelic frequencies were higher in DLB, relative to PDD subjects, for BuChE-K (P = 0.06), APOE e4 (P < 0.001), or both alleles together (P < 0.001). More rapid cognitive decline was seen in PDD patients carrying both alleles, compared with other genotypes. Subjects with hyperhomocysteinemia were associated with more rapid decline in the presence of BuChE-K, with or without APOE ε4. These results suggest that genetic and biochemical risk factors for AD and PDD pathology may be important in dementia onset and progression in these Lewy body disorders.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0></fA01><fA03 i2="1"><s0>Mov. disord.</s0></fA03><fA05><s2>24</s2></fA05><fA06><s2>3</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>BuChE-K and APOE ε4 Allele Frequencies in Lewy Body Dementias, and Influence of Genotype and Hyperhomocysteinemia on Cognitive Decline</s1></fA08><fA11 i1="01" i2="1"><s1>LANE (Roger)</s1></fA11><fA11 i1="02" i2="1"><s1>YUNSHENG HE</s1></fA11><fA11 i1="03" i2="1"><s1>MORRIS (Christopher)</s1></fA11><fA11 i1="04" i2="1"><s1>LEVERENZ (James B.)</s1></fA11><fA11 i1="05" i2="1"><s1>EMRE (Murat)</s1></fA11><fA11 i1="06" i2="1"><s1>BALLARD (Clive)</s1></fA11><fA14 i1="01"><s1>Novartis Pharmaceuticals Corporation</s1><s2>East Hanover, New Jersey</s2><s3>USA</s3><sZ>1 aut.</sZ></fA14><fA14 i1="02"><s1>Clinical Pharmacogenetics, Novartis Pharmaceuticals Corporation</s1><s2>Cambridge, Massachusetts</s2><s3>USA</s3><sZ>2 aut.</sZ></fA14><fA14 i1="03"><s1>Newcastle General Hospital</s1><s2>Newcastle upon Tyne</s2><s3>GBR</s3><sZ>3 aut.</sZ></fA14><fA14 i1="04"><s1>VA-Puget Sound Health Care System (MIRECC, PADRECC) and University of Washington</s1><s2>Seattle, Washington</s2><s3>USA</s3><sZ>4 aut.</sZ></fA14><fA14 i1="05"><s1>Istanbul Faculty of Medicine, Istanbul University</s1><s2>Istanbul</s2><s3>TUR</s3><sZ>5 aut.</sZ></fA14><fA14 i1="06"><s1>Wolfson Centre for Age Related Diseases, King's College</s1><s2>London</s2><s3>GBR</s3><sZ>6 aut.</sZ></fA14><fA20><s1>392-400</s1></fA20><fA21><s1>2009</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20953</s2><s5>354000186999840110</s5></fA43><fA44><s0>0000</s0><s1>© 2009 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>22 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>09-0136787</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Movement disorders</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Apolipoprotein E (APOE) e4 and butyrylcholinesterase-K (BuChE-K) are associated with an increased risk for Alzheimer's disease. The primary objective was to evaluate frequencies of these alleles in dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD). A secondary objective was to evaluate influences on rate of cognitive decline. This analysis used data from participants consenting to pharmacogenetic testing in placebo-controlled rivastigmine studies. Allele frequencies in DLB and PDD were compared using logistic regression. Within the PDD placebo sample, associations with cognitive decline were evaluated (the DLB sample was too small for these evaluations). Fifty-seven DLB and 323 PDD subjects provided APOE and BuChE data. Allelic frequencies were higher in DLB, relative to PDD subjects, for BuChE-K (P = 0.06), APOE e4 (P < 0.001), or both alleles together (P < 0.001). More rapid cognitive decline was seen in PDD patients carrying both alleles, compared with other genotypes. Subjects with hyperhomocysteinemia were associated with more rapid decline in the presence of BuChE-K, with or without APOE ε4. These results suggest that genetic and biochemical risk factors for AD and PDD pathology may be important in dementia onset and progression in these Lewy body disorders.</s0></fC01><fC02 i1="01" i2="X"><s0>002B17</s0></fC02><fC02 i1="02" i2="X"><s0>002B17G</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Démence à corps de Lewy</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Lewy body dementia</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Demencia cuerpos Lewy</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Hyperhomocystéinémie</s0><s2>NM</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Hyperhomocysteinemia</s0><s2>NM</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Hiperhomocisteinemia</s0><s2>NM</s2><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Trouble cognitif</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Cognitive disorder</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Trastorno cognitivo</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Maladie de Parkinson</s0><s2>NM</s2><s5>04</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Parkinson disease</s0><s2>NM</s2><s5>04</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Parkinson enfermedad</s0><s2>NM</s2><s5>04</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>05</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Génotype</s0><s5>10</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Genotype</s0><s5>10</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Genotipo</s0><s5>10</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Apolipoprotéine E</s0><s5>11</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Apolipoprotein E</s0><s5>11</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Apolipoproteína E</s0><s5>11</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du système nerveux central</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>40</s5></fC07><fN21><s1>096</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist><affiliations><list><country><li>Royaume-Uni</li><li>Turquie</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Grand Londres</li><li>Massachusetts</li><li>New Jersey</li><li>Washington (État)</li></region><settlement><li>Londres</li><li>Seattle</li></settlement><orgName><li>Université de Washington</li></orgName></list><tree><country name="États-Unis"><region name="New Jersey"><name sortKey="Lane, Roger" sort="Lane, Roger" uniqKey="Lane R" first="Roger" last="Lane">Roger Lane</name></region><name sortKey="Leverenz, James B" sort="Leverenz, James B" uniqKey="Leverenz J" first="James B." last="Leverenz">James B. Leverenz</name><name sortKey="Yunsheng He" sort="Yunsheng He" uniqKey="Yunsheng He" last="Yunsheng He">YUNSHENG HE</name></country><country name="Royaume-Uni"><noRegion><name sortKey="Morris, Christopher" sort="Morris, Christopher" uniqKey="Morris C" first="Christopher" last="Morris">Christopher Morris</name></noRegion><name sortKey="Ballard, Clive" sort="Ballard, Clive" uniqKey="Ballard C" first="Clive" last="Ballard">Clive Ballard</name></country><country name="Turquie"><noRegion><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F59 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000F59 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:09-0136787
|texte= BuChE-K and APOE ε4 Allele Frequencies in Lewy Body Dementias, and Influence of Genotype and Hyperhomocysteinemia on Cognitive Decline
}}
| This area was generated with Dilib version V0.6.23. |  |